Azithromycin Reduction to Reach Elimination of Trachoma

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Dec 2, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the best approach to eliminate trachoma, an eye infection that can lead to blindness, in certain communities in Maradi, Niger. Researchers want to find out if stopping or continuing the annual distribution of azithromycin, an antibiotic, is more effective in reducing the infection in communities where the disease is still present but at a lower level. The trial will involve randomly assigning 80 communities, where up to 20% of people have signs of trachoma, to either continue receiving the medication for three more years or to stop receiving it.

To participate in this trial, individuals must be residents of one of the selected communities and agree to follow all study guidelines. They also need to give their consent to take part in the research. Participants can expect to be part of a careful study that aims to improve health outcomes in their community, and their involvement will help researchers understand the best way to combat this disease. Overall, this trial is important because it seeks to find the most effective methods to eliminate trachoma and protect people's vision in these communities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of appropriate informed consent
• • Stated willingness to comply with all study procedures
• • Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
• Exclusion Criteria:
• • Does not consent to participation
• • Unwilling to comply with all study procedures
• • Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial